NORTHBROOK, Ill., July 23 /PRNewswire/ -- Horizon Pharma, Inc. announced today the results from the extended open label portion of The Circadian Administration of Prednisone in Rheumatoid Arthritis-1 (CAPRA-1) Phase 3 European registration study of LODOTRA®, a programmed release formulation of low-dose prednisone, which showed sustained improvement in reducing the duration of morning stiffness in patients with Rheumatoid Arthritis (RA) over a 12 month period.
'HOT TOPICS' From the Alzheimer's Association International Conference on Alzheimer's Disease 2010
-
- New Alzheimer's Risk Gene May Affect Memory Scores and Brain Atrophy in Middle Age -
- Clinical Trial of Intranasal Insulin Shows Benefits in Alzheimer's and MCI -
- Known Alzheimer's Risk Gene May Change Shape of Brain Deposits -
HONOLULU, July 14 /PRNewswire-USNewswire/ -- Last minute scientific submissions to the Alzheimer's Association International Conference on Alzheimer's Disease 2010 (AAICAD 2010) in Honolulu, HI, known as "hot topics," suggest that (1) a newly-discovered risk gene for Alzheimer's may have early impact on memory skills and brain volume, (2) intranasal insulin may be beneficial in Alzheimer's, and (3) beta amyloid deposits in the brains of people with Alzheimer's disease may take different shapes based on a ...
Announcing XCell-Imaging, the World’s First High-Definition MRI and CT Imaging Center for Specialized Stem Cell Applications and Diagnostics
The XCell-Center GmbH has teamed up with GE healthcare technology to bring its patients the latest in GE imaging technology: the newly introduced Signa Series 3.0 Tesla magnetic resonance scanner (MRI) and the new Discovery HD CT 750 scanner (CT) for applied diagnostics.
Helix BioPharma Corp. Announces Positive Phase II Pharmacokinetic Findings for Topical Interferon Alpha-2b in Patients With Low-Grade Cervical Lesions
AURORA, Ontario, June 23 /PRNewswire-FirstCall/ -- Helix BioPharma Corp. (TSX, FSE: "HBP" / OTCQX: HXBPF) today announced positive Phase II pharmacokinetic ("PK") findings for Topical Interferon Alpha-2b in patients with low-grade cervical lesions.
Horizon Pharma, Inc. Presents Results of Phase 3 Studies of LODOTRA(R) Demonstrating Statistically Significant Improvement in Response in Rheumatoid A
NORTHBROOK, Ill., June 16 /PRNewswire/ -- Horizon Pharma, Inc., announced today that data from the Phase 3 U.S. registration study of LODOTRA®, a circadian cytokine modulator and novel modified-release, low-dose prednisone tablet, showed a statistically significant improvement in American College of Rheumatology (ACR) response criteria in patients with rheumatoid arthritis (RA).
XCell-Center GmbH Gets Approval by French Health Authorities to Conduct Clinical Trial with Stem Cells for Chronic Spinal Cord Injury
XCell-Center GmbH, Europe's leading provider of adult autologous stem cell therapy, announced approval of the first placebo controlled double blind clinical trial in patients with chronic spinal cord injury.
Horizon Pharma Announces LODOTRA(R) and DUEXA(R) Data to be Presented at the European League Against Rheumatism (EULAR) Annual Congress
NORTHBROOK, Ill., June 9 /PRNewswire/ -- Horizon Pharma, Inc., today announced that data on its two lead product candidates, LODOTRA®, a circadian cytokine modulator and novel modified release, low-dose prednisone tablet, and DUEXA®, a proprietary tablet formulation containing a fixed-dose combination of ibuprofen and high-dose famotidine, will be presented during the European League Against Rheumatism (EULAR) Annual Congress taking place in Rome, Italy, June 16-19.
Statistics Confirm Spinal Cord Injury Patients Improving After Stem Cell Therapy
The XCell-Center has released encouraging results from a follow-up study of 140 spinal cord injury patients treated with autologous bone marrow stem cells. Overall, nearly 60% improved following treatment.
XCell-Center Presents Impressive Results from Cerebral Palsy Stem Cell Treatment
The XCell-Center, Europe’s leading stem cell therapy provider has released impressive results from a follow-up study of 100 cerebral palsy patients treated with autologous bone marrow stem cells. Overall, 67% improved following treatment.
Safety Follow-up of Adult Stem Cell Patients Yields Promising Results
The XCell-Center has completed a promising safety follow-up of 870 patients who were treated by lumbar puncture for various indications such as spinal cord injury, Parkinson's disease, cerebral palsy, and more. Patients were surveyed 10 days after treatment and again after 3 months.
Majority of Parkinson’s Patients Improved After German Stem Cell Treatment
The XCell-Center, Europe’s leading stem cell therapy provider has released results from a follow-up study of 50 Parkinson’s disease patients treated with autologous bone marrow stem cells. Overall, almost 60% improved following treatment.
Stem Cell Therapy News Now Available on Twitter
The XCell-Center announces the official launch of its stem cell therapy news campaign on Twitter.com to meet the demand of prospective and treated patients who wish to receive real-time updates on treatment success stories, newly available treatments and other newsworthy events.
Cerebral Palsy Patient Still Improving after 2nd Round of Stem Cells in Germany
Sophia Chang, a 3 year-old girl from Woodland Hills, California, is continuing to improve following her second stem cell treatment since March 2008 for cerebral palsy at the XCell-Center in Dusseldorf, Germany.
The XCell-Center Treats its 2000th Stem Cell Patient in Germany
The XCell-Center is pleased to report treating its 2000th stem cell patient at its state-of-the-art clinic in Dusseldorf, Germany.
US Heart Failure Patient ‘Back to Normal’ After Stem Cell Treatment in Germany
After suffering three heart attacks prior to being diagnosed with heart failure in 1994, Aaron Wood of Waurika, Oklahoma, says that he can finally live a normal life after his successful stem cell treatment at the XCell-Center in Dusseldorf, Germany.
